MedPath

Effectiveness of intraosseous tranexamic acid combined with intravenous tranexamic acid in hip arthroplasty

Phase 4
Conditions
Osteoarthritis of hip
Hip arthroplasty
Registration Number
TCTR20200511002
Lead Sponsor
arathorn Kongsakpaisal
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
50
Inclusion Criteria

Adult patients diagnoses as osteoarthritis of hip and undergoing cementless total hip arthroplasty

Exclusion Criteria

- Allergy to tranexamic acid
- Coagulopathy
- Severe renal impairment
- History of venous thromboembolism
- History of ischemic heart disease, ischemic stroke
- History of seizure

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total blood loss from total hip arthroplasty 3 days Intraoperative blood loss+ Drainage+ Hb change
Secondary Outcome Measures
NameTimeMethod
Complications : venous thromboembolism 1 week Monitor sign and symptoms of VTE, if suspect, then further investigations will be done.
© Copyright 2025. All Rights Reserved by MedPath